Cara rounds up $15M for post-op pain drug

Connecticut-based Cara Therapeutics has landed $15 million in Series D financing with help from new investor Rho Ventures, which led the round. Cara is developing CR845, an intravenous post-operative pain treatment currently being studied in a Phase II clinical trial in women following laparoscopic hysterectomy. The financing will be used to support further clinical development of CR845.

"There has been little innovation in post-operative pain treatment where opioid use continues to be the standard of care even though it is associated with significant side effects which present an ongoing pharmacoeconomic burden for hospitals," said Rho Ventures partner Martin Vogelbaum in a statement. "Due to its peripheral activity and lack of CNS penetration, we believe Cara's CR845 has a chance to provide opioid-like pain relief while significantly reducing opioid use and its associated side effects." Cara has raised more than $43 million in funding since opening its doors..

- here's Cara's release

Suggested Articles

MicuRx nabbed $7.78 million from a nonprofit focused on antimicrobial resistance to push its third antimicrobial program into human trials.

The FDA has handed Scholar Rock a rare pediatric disease designation voucher, which can allow the biotech a speedy review of its SMA med.

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.